2016
Vaccination strategies against respiratory syncytial virus
Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, Galvani AP. Vaccination strategies against respiratory syncytial virus. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 13239-13244. PMID: 27799521, PMCID: PMC5135296, DOI: 10.1073/pnas.1522597113.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSyncytial virusVaccination strategiesAge-specific vaccination strategiesRSV vaccine candidatesSubstantial indirect protectionInfectious viral loadOngoing clinical trialsWeekly incidence ratesTargeting of childrenDifferent age groupsInfected childrenRSV vaccinationVaccination uptakeInfant hospitalizationViral loadVaccine mechanismVaccination programClinical trialsIncidence rateCommon causeRSV incidenceVaccine candidatesAge groupsRSV symptomsCost-effectiveness of next-generation vaccines: The case of pertussis
Fitzpatrick MC, Wenzel NS, Scarpino SV, Althouse BM, Atkins KE, Galvani AP, Townsend JP. Cost-effectiveness of next-generation vaccines: The case of pertussis. Vaccine 2016, 34: 3405-3411. PMID: 27087151, DOI: 10.1016/j.vaccine.2016.04.010.Peer-Reviewed Original ResearchConceptsNext-generation vaccinesDuration of protectionAdult boostersChildhood seriesAge-structured transmission modelVaccination coverage ratesCases of pertussisPublic health challengePerfect efficacyPertussis vaccinationPertussis vaccinePertussis incidenceCurrent vaccinesNew vaccinesPotential vaccinesGreater efficacyVaccineVaccine improvementHealth challengesAverage durationHealth benefitsEfficacyDoseShort durationPertussis
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug useOptimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US
Alfaro-Murillo JA, Townsend JP, Galvani AP. Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US. Vaccine 2015, 34: 225-229. PMID: 26631416, DOI: 10.1016/j.vaccine.2015.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCytomegalovirus InfectionsCytomegalovirus VaccinesDisease Transmission, InfectiousFemaleHumansImmunization ScheduleInfantInfant, NewbornInfectious Disease Transmission, VerticalMaleMass ScreeningMiddle AgedUnited StatesYoung AdultConceptsVaccine waningVaccine efficacyOptimal ageCMV vaccine candidatesLongitudinal clinical evaluationChild-bearing yearsYears of ageTransmission dynamicsCMV prevalenceCMV vaccinationCytomegalovirus ScreeningSeronegative femalesCongenital infectionCytomegalovirus infectionVaccine protectionSuch vaccinationClinical evaluationClinical trialsHearing lossVaccine candidatesVaccinationDemographic dataCongenital diseaseCognitive deficitsIndirect protection
2013
Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty
Mbah M, Medlock J, Meyers LA, Galvani AP, Townsend JP. Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty. Vaccine 2013, 31: 3079-3089. PMID: 23684837, PMCID: PMC3764605, DOI: 10.1016/j.vaccine.2013.04.052.Peer-Reviewed Original ResearchConceptsOptimal vaccine allocationParameter uncertaintiesMathematical modelProbability distributionConsideration of uncertaintiesOutcome measuresVaccine allocationHuman population immunitySeasonal influenza vaccinationControl of influenzaUncertainty analysisFace of uncertaintyInfluenza vaccinationVaccine efficacySeasonal influenzaPopulation immunityUncertaintyEpidemiological dataHigh riskYounger ageYoung adultsEpidemiological parametersOptimal agePrevious recommendationsVaccineCost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa
Mbah M, Kjetland EF, Atkins KE, Poolman EM, Orenstein EW, Meyers LA, Townsend JP, Galvani AP. Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 7952-7957. PMID: 23589884, PMCID: PMC3651507, DOI: 10.1073/pnas.1221396110.Peer-Reviewed Original ResearchConceptsCommunity-based interventionsHIV infectionHIV transmissionSchistosoma haematobiumFemale genital schistosomiasisAdministration of praziquantelSaharan AfricaRural ZimbabweS. haematobium transmissionGenital schistosomiasisGenital infectionHealth payersSchool-aged childrenIntervention periodEpidemiological dataEpidemiological studiesS. haematobiumSchistosomiasis prevalenceHealth educationInfectionSchistosomiasisYoung womenHaematobiumInterventionHIV